BTG halts cancer drug production

Healthcare group BTG said yesterday it has recently had to stop production of one of its cancer treatment drugs, after the US Food and Drug Administration (FDA) raised concerns over its production at a site based in Oxford, Connecticut. “We are working to identify and implement processes and procedures to address these concerns,” the firm said in a statement. BTG also said yesterday that its full-year revenues are expected to be in line with previous forecasts, coming in somewhere between £235m and £245m.